NCT02260050已完成1 期
Bioequivalence of 20 mg of the New Formulation of WAL 801 CL Dry Syrup Compared to 20 mg of the Conventional Formulation of WAL 801 CL Dry Syrup Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, 2x2 Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 主要终点
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to last measurable concentration (AUC0- tz)
研究概览
简要总结
To establish the bioequivalence of the new formulation of WAL 801 CL dry syrup vs. the conventional formulation of WAL 801 CL dry syrup
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature (BT)), 12-lead ECG, clinical laboratory tests (including gastric acidity (GA) test)
- •No finding of clinical relevance
- •No evidence of a clinically relevant concomitant disease
- •Age ≥ 20 and Age ≤ 35 years
- •BMI ≥ 18.5 and BMI ≤ 25 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to Screening Phase and prior to Treatment Phase (Day -1 in Treatment period 1) in accordance with Japanese Good Clinical Practice (GCP)
排除标准
- •Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •History of surgery of gastrointestinal tract with the exception of appendectomy
- •History of (and/or current) diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Current chronic or relevant acute infections
- •History of hypersensitivity (including drug allergy) or current allergic disorders which are deemed relevant to the trial by the investigator or the sub-investigators; e.g. bronchial asthma, allergic rhinitis, atopic dermatitis and food allergy (excluding asymptomatic seasonal rhinitis/hay fever)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to drug administration and during Treatment Phase
- •Use of any drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation, within 10 days prior to administration and during Treatment Phase
- •Participation in Phase I trial of new chemical entities within 4 months prior to drug administration and during the trial, or in another clinical trial within 3 months prior to drug administration and during Treatment Phase
- •Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
- •Inability to refrain from smoking during hospitalization
- •Alcohol abuse (more than 60 g/day) (confirmed by interview)
- •Drug abuse (confirmed by interview)
- •Whole blood donation (400 mL within 3 months or more than 100 mL within 4 weeks prior to drug administration or during the trial) or component blood donation (within 2 weeks prior to drug administration or during Treatment Phase)
- •Excessive physical activities (within 48 hours prior to each treatment period and during hospitalisation)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
研究组 & 干预措施
WAL 801 CL new formulation
Experimental
干预措施: WAL 801 CL dry syrup new formulation (Drug)
WAL 801 CL conventional formulation
Active Comparator
干预措施: WAL 801 CL dry syrup conventional formulation (Drug)
结局指标
主要结局
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to last measurable concentration (AUC0- tz)
时间窗: up to 34 hours after drug administration
Maximum measured concentration of the analytes in plasma (Cmax)
时间窗: up to 34 hours after drug administration
次要结局
- Terminal rate constant of the analyte in plasma (λz)(up to 34 hours after drug administration)
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)(up to 34 hours after drug administration)
- Terminal half-life of the analyte in plasma (t1/2)(up to 34 hours after drug administration)
- Mean residence time of the analyte in the body after po administration (MRTpo)(up to 34 hours after drug administration)
- Number of patients with clinically significant findings in laboratory tests(up to 34 hours after last drug administration)
- Number of patients with clinically significant findings in vital signs(Up to 34 hours after last drug administration)
- Number of patients with adverse events(Up to 48 hours after last drug administration)
- Time from dosing to the maximum concentration of the analyte in plasma (tmax)(up to 34 hours after drug administration)
- Number of patients with clinically significant findings in physical examination(up to 34 hours after last drug administration)
研究者
相似试验
已完成
1 期
A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult MalesHealthy AdultNCT01506739Eisai Co., Ltd.12
已完成
1 期
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid TumorsLung Cancer, Small CellNCT00259935GlaxoSmithKline107
已完成
1 期
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.Acquired Immunodeficiency SyndromeNCT02583464Laboratorio Elea Phoenix S.A.24
已完成
1 期
Study to Compare 2 Formulations of LY900014 in Healthy ParticipantsHealthyNCT03616977Eli Lilly and Company69
已完成
1 期
A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy SubjectsHealthyNCT02821338Food and Drug Administration (FDA)30